Thermo Fisher Scientific IL-22 Polyclonal Antibody, Biotin

Applications

Tested Dilution

Publications

Western Blot (WB)

1:1,000-1:2,000

-

ELISA (ELISA)

1:20,000-1:50,000

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Anti-IL-22 antibody was prepared from rabbit antiserum after repeated immunizations with a truncated form of recombinant human IL-22 protein from E. coli.

Conjugate

Biotin Biotin Biotin

Form

Lyophilized

Concentration

1 mg/mL

Purification

Ion-exchange chromatography

Storage buffer

0.02M potassium phosphate, pH 7.2, with 10mg/mL BSA, 0.15M NaCl

Contains

0.01% sodium azide

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Ambient (domestic); Wet ice (international)

Product Specific Information

Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

Anti-IL-22 is an IgG fraction antibody purified from monospecific antiserum by a multi-step process which includes delipidation, salt fractionation and ion exchange chromatography followed by extensive dialysis against the buffer stated above. This antibody is specific for human IL-22 protein. A BLAST analysis was used to suggest cross-reactivity with IL-22 from human sources based on 100% homology with the immunizing sequence. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Biotin and anti-Rabbit Serum. Cross-reactivity with IL-22 from other sources has not been determined.

Target Information

IL-22 also known as IL-10-related T-cell derived inducible factor, is an alpha helical cytokine and is considered a member of the IFN-IL-10 family, which includes IL-19, IL-20, IL-24, IL-26, IL-28, IL-29, and the type I and II interferons. IL-22 is produced mainly by activated T cells and NK cells. In humans, the IL-22 gene is located on the q arm of chromosome 12, and is structurally related to IL10. IL-22 acts by engaging the heterodimeric receptor complex consisting of primary receptor IL-22R1 and accessory receptor IL-10R2. IL-22R1 also binds IL-20 and IL-24; IL-10R2 also binds IL-10, IL-27, IL-28, and IL-29. Binding of IL-22 to its receptor complex induces signal transduction, particularly via the JAK-STAT pathway. In addition to the membrane-bound IL-22R1/IL-10R2 complex, a soluble single-chain IL-22 receptor termed IL-22BP has been found to antagonize IL-22 binding and signaling. IL-22 appears not to directly influence immune cells, and major targets of the cytokine appear to be nonimmune cells, such as cells of the skin, digestive and respiratory system, as well as hepatocytes, and keratinocytes. IL-22 has been described as an effector cytokine of the Th17 lineage. Along with IL-17A and IL-17F, IL-22 regulates genes associated with innate immunity of the skin. IL-17A, IL-17F and IL-22 are all co-expressed by Th17 cells, however, they are differentially regulated. The effects of IL-22 include induction of acute phase reactants and antimicrobial proteins, as well as increasing the mobility of keratinocytes. IL-22 is highly expressed during chronic inflammation, and found to activate intracellular kinases and transcription factors. IL-22 is critical for host defense against infections of extracellular pathogens, and promotes wound-healing responses. IL-22 is upregulated in activated T cells. IL-22 has been reported to mediate IL-23-induced acanthosis and dermal inflammation through activation of STAT3.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.